Why Mexidol®?

Time codes:
  • 01:02

    History of the drug Mexidol®

  • 01:40

    The mechanism of action of the drug Mexidol®

  • 03:03

    Mexidol® - pharmacological effects

  • 03:54

    Clinical effects and safety of Mexidol®

  • 04:30

    Security Profile

  • 05:09

    The optimal dose and duration of intravenous infusion and intramuscular injection

  • 05:50

    Mexol 125 mg, Mexidol® Fort 250 mg transition

  • 06:20

    Evidence base of the effectiveness of Mexidol

  • 06:45

    The results of the study of Epic

  • 08:16

    Clinical recommendations

  • 09:40

    Differences in Mexidol® and analogues.

Schukin Ivan Aleksandrovich - Ph.D., Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics LF RNIMU named after N.I. Pirogov

Announcement:

Schukin Ivan Alexandrovich - candidate of medical sciences, associate professor of the Department of Neurology of the Russian State Medical University, answers the main questions about the drug Mexol®. Why is Mexidol® so widely prescribed and popular among doctors and patients? What pharmacological and clinical effects does it have? What is the evidence base and methods of using the drug Mexidol®? Let's figure it out!

Block of articles on this topic

Mexidol: a spectrum of pharmacological effects

Author:
Voronina T.A.

Nii pharmacology named after V.V. Zakusov RAMS, Moscow

Original and reproduced drugs: what do the clinician need to know?

Author:
A.V. Schulkin, A.A. Filimonova
FSBEI in the Ryazan State Medical University of the Ministry of Health of Russia, Ryazan, Russia

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

Authors:

L.V. Stakhovskaya 1 , N.A. Shamalov 1 , DR Khasanova 2 , E.V. Melnikova 3 , A.S. Agafin 4 , K.V. Golikov 5 , E.I. Bogdanov 6 , A.A. Yakupova 6 , L.V. Roshkovskaya 7 , L.V. Lukin 8 , T.M. Lokstanova 9 , I.E. Patrunenova 10 , L.A. Shchepankevich 11

1 Research Institute of Cerebrovascular Pathology and Stroke of the Federal State Budgetary Institution “Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
2 Igauz "Interregional Clinical and Diagnostic Center", Kazan, Russia;
3 St. Petersburg GBUZ "City Hospital No. 26", St. Petersburg, Russia;
4 St. Petersburg GBUZ "City Hospital No. 40 of the Resort Administrative District", St. Petersburg, Russia;
5 St. Petersburg GBUZ "City multidisciplinary hospital No. 2", St. Petersburg, Russia;
6 FSBEI in Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia;
7 St. Petersburg GBUZ "Nikolaev Hospital", St. Petersburg, Russia;
8 GBUZ "Vsevolozhsk Clinical Interdistrict Hospital", Leningrad Region, Russia;
9 Mubz "City Clinical Hospital No. 1 named after N.I. Pirogov ", Samara, Russia;
10 GBUZ "Samara Regional Clinical Hospital named after V.D. Seredavina ”, Samara, Russia;
11 FGBNU "Scientific Institute of Experimental and Clinical Medicine", Novosibirsk, Russia.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2017, No. 3, issue 2

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com